Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases?

World Journal of Surgery

Volumn 31, Issue 12, 2007, Pages 2392-2397

  Hung, Ji Shiang ^a   Chang, Ming Chu ^a   Lee, Po Huang ^a   Tien, Yu Wen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; FLUOROURACIL; STREPTOZOCIN;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATIC ARTERY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; NEUROENDOCRINE TUMOR; PANCREAS RESECTION; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PROSPECTIVE STUDY; QUALITY OF LIFE; SPLENECTOMY; TELEPHONE; TREATMENT DURATION; TREATMENT INDICATION; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EMBOLIZATION, THERAPEUTIC; FEMALE; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; SOMATOSTATIN; SPLENECTOMY;

EID: 36849091372     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-007-9264-3     Document Type: Article

References (32)

1. Mignon M (2000) Natural history of neuroendocrine enteropancreatic tumors. Digestion 62:51-58
2. Ramage JK, Davies AHG, Ardill J, et al. (2005) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumors. Gut 54(suppl IV):iv1-iv16
3. Holen K (2006) Therapeutic and palliative options for diffuse neuroendocrine metastatic disease. J Gastrointest Surg 10:337-340
4. Arnold R (2005) Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 19:491-505
5. Dixon E, Pasieka JL (2007) Functioning and nonfunctioning neuroendocrine tumors of the pancreas. Curr Opin Oncol 19:30-35
6. de Herder WW (2004) Gut endocrine tumors. Best Pract Res Clin Gastroenterol 18:477-495
7. Bloomston M, Muscarella P, Shah MH, et al. (2006) Cytoreduction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas. J Gastrointest Surg 10:1361-1370
8. Chamberlain RS, Canes D, Brown KT, et al. (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190:432-445
9. Nave H, Mossinger E, Feist H, et al. (2001) Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 129:170-175
10. Norton JA (2005) Surgical treatment of neuroendocrine metastases. Best Pract res Clin Gastroenterol 19:577-583
11. Norton JA, Warren RS, Kelly MG, et al. (2003) Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134:1057-1065
12. Schell SR, Camp ER, Caridi FG, et al. (2002) Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 6:664-670
13. Gupta S, Johnson MM, Murthy R, et al. (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104:1590-1602
14. Berber E, Flesher N, Siperstein AE (2002) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26:985-990
15. Gillams A, Casssoni A, Conway G, et al. (2005) Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 30:435-441
16. O'Toole D, Maire F, Ruszniewski P (2003) Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 10:463-468
17. Sarmiento JM, Heywood G, Rubin J, et al. (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29-37
18. Osborne DA, Zervos EE, Strosberg J, et al. (2006) Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13:572-581
19. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, et al. (2006) Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl 12:448-456
20. Pascher A, Klupp J, Neuhaus P (2005) Transplantation in the management of metastatic endocrine tumors. Best Pract Res Clin Gastroenterol 19:637-648
21. Nortan JA, Kivlen M, Li M, et al. (2003) Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 138:859-866
22. Kazanjian KK, Reber HA, Hines OJ (2006) Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141:765-769
23. Yao JC, Vauthey JN (2003) Primary and metastatic hepatic carcinoid: is there an algorithm? Ann Surg Oncol 10:1133-1135
24. House MG, Cameron JL, Lillemoe KD, et al. (2006) Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg 10:138-145
25. Chen H, Hardacre JM, Uzar A, et al. (1998) Isolated liver metastases from neuroendocrine tumors: does resection prolonged survival? J Am Coll Surg 187:88-93
26. Florman S, Toure B, Kim L, et al. (2004) Liver transplantation for neuroendocrine tumors. J gastrointest Surg 8:208-212
27. Sutcliffe R, Maguire D, Ramage J, et al. (2004) Management of neuroendocrine liver metastases. Am J Surg 187:39-46
28. Solorzano CC, Lee JE, Pisters PW, et al. (2001) Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130:1078-1085
29. Metz DC, Benjamin SB (1991) Islet cell carcinoma of the pancreas presenting as bleeding from isolated gastric varices: report of a case and review of the literature. Dig Dis Sci 36:241-244
30. Faiss S, Pape UF, Böhmig M, et al. (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the international Lanreotide and interferon Alfa study group. J Clin Oncol 21:2689-2696
31. Ducreux M, Ruszniewski P, Chayvialle JA, et al. (2000) The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95:3276-3281
32. Moertel CG (1987) Karnofsky Memorial Lecture: an odyssey in the land of small tumors. J Clin Oncol 5:1503-1522